Plant Health Care Share Discussion Threads

[blackswann] 23/7/2022 07:33

Hello all. Just looking at the current valuation of the company on a price to sales ratio & a EV/sales and it seems reasonable given the projected 2025 revenue target. Questions though.What is 2022, 2023 & 2024 sales targetsWhat PSR or EV/sales multiple are our competitors on or could you give me the names of some of our competit so I can research myself please.Thankyou

[pretax2] 22/7/2022 11:27

RE: Scale in slowly
Sounds wise BlackSwann. And thanks for info on the options (I was looking for that the other day).
My gut feeling is that the directors will be able to sweep all these options off the table before 2027.

[blackswann] 22/7/2022 09:38

Hi, there were x2 lots of options granted at a 1p strike rateThe first batch of which there are just over 3m left.70% of these can be take if the share price AVERAGE over a 30 day period is 15p. The remaining 30% can be taken if the average share price over a 30 say period is 27p.The second batch of which there are just under 5m left.70% of these can be taken if the share price average over 30 days is 22p with the remaining available if share price average over 30 days hits 33p.Both batches expire in 2027.Options is one thing but proper skin in the game is the other. I like these a lot but the lack of director own money in is a bit of a ,let's say Amber flag. Not a red flag.A decent buy from a director at this level would complete the investment case for me and I would go all in. At present I think I'll scale in slowly just incase

[pretax2] 22/7/2022 08:35

Blackswann
There is an interview from earlier this year where CR says that Ospraie we’re approach by a fund and asked if they would sell some of their stock to them.
As for JT, I’ve also puzzled over why he doesn’t have more of a stake. The directors have performance related options with a strike of 1p. CR told me they vest much higher, but didn’t say how high. So if I’m JT I might ask ‘do I want 2m shares at 10p right now or 2m at 1p when the share-price is significantly higher?’ If I’m confident that the price is going up, I’d hang on for the options.
I’ve never been seduced into thinking that the current share-price reflects the value or potential of PHC, but sometimes you have to wait for Mr Market to come to his senses.
Sorry for long winded reply.

[blackswann] 22/7/2022 07:22

Yes that is true. Revenue growth is great & I can see the companies pathway to higher revenues in the future given their ambition to release x1 new product each year and organic growth of PREtec 279 as well as HarpinAB. Institution sells are not a concern in isolation but with x2 of them reducing holdings and the lack of real skin in the game from the CEO & CFO does make me cautious. It's the only thing holding me back taking a position here. I am interested though. What are peoples hopes for the presentation?

[pretax2] 22/7/2022 06:58

A 60% increase in H1 sales is a better indicator of company health than institutional and director dealing. There are many indirect factors influencing institutional and director dealing. I’ve known institutions offloading just before share prices go on huge bull runs. Sometimes to create liquidity in the stock. Look at i3e. There were 5x institutional sells just before the had a 300% rise.

[blackswann] 21/7/2022 22:00

While there are a lot of options on the table, the board (not counting Chris) don't really have enough skin in the game. I would like Mr Tweedy to get serious now he is in the big seat and put a decent chunk of his own money on the line. After all, if he isn't, why should we? If we're truly at that inflexion point.Anyone got any good questions they're going to ask on the 25th?

[r0hini] 21/7/2022 21:50

Isn't it a worry for anyone that Ospraie & now Lombard have reduced their holding?Lombard still own 5% of the company after previously holding 7.4%.Are they dumping their entire holding as that's 15m shares to churn through

[cerrito] 21/7/2022 19:06

I am encouraged that Lombard Odier can reduce their holding by 5% of the shares outstanding and the share price more or less takes it in its stride.

[pretax2] 18/7/2022 13:52

They've repeatedly said no more raises over the last 3 months. There're quite a few performance related options on the table though. They vest much higher.
It's a long-term hold here, but I can see the company being taken over by a distributer like Nutrien or Wilbur-Ellis. It's taken them years of research, but PreTec just works like magic.

[geraldus] 18/7/2022 12:16

Very satisfactory update and a confident outlook.If the market believes they won't raise any more funds this should grow as well as the plants. Gla.

[pretax2] 18/7/2022 09:06

Results look good well done JT (again)

In particular these bits:
-------------------------------------
"Sales in North America were up 133% to $1.4 million (H1 2021: $0.6 million). In South America, sales were up 333% to $1.3 million (H1 2021: $0.3 million), primarily driven by the full-scale launch of Saori (see below), and strong demand for H2Copla (Harpin αβ) from sugar cane processors. In Mexico, revenue was up 31% to $1.7 million (H1 2021: $1.3 million) following a strong bounce-back in the vegetable markets and expansion into the agave and avocado markets."

"Nutrien expects to treat approximately 150,000 hectares of soybeans in 2022, expanding to more than one million hectares by 2025. The Company's revenue from sales of Saori to Nutrien is expected to grow to more than $5 million by 2025."
------------------------------------
In short the impact of PreTec is going to be HUGE.

[cerrito] 13/7/2022 23:22

Thanks for highlighting this interview that passed me by. Good to hear him be so optimistic about no need for a further fund raising.
The mind boggles as to the number of shares they would have to issue at current exchange rates and of course the share price.

[pretax2] 13/7/2022 22:37

Cheers P4Boy
Interesting that they released this before the interims (only 2 weeks away). Essentially what they're saying is that the company is on a positive growth track and to ignore the crazy markets.
Reckon most investors know that and are holding for the long game, but it a good bit of PR to give investors a boost. Well done JT.

[pretax2] 08/7/2022 07:21

Nice to see a bounce off a support line. It been a long slide down, but I know for a fact that some great companies who are making truckloads of cash have also slid back (e.g. i3e). That’s the broader market recession jitters for you.
Roll on PHC interims this month.

[oapknob1] 07/7/2022 22:17

Who knows, makes the time, doesn't expect it to happen!The 2023 crop is already underway in this great producer of Goias. No matter the variety of sugarcane, H2COPLA is ensuring the full development of the plant in the pursuit of best productivity.In April, H2COPLA was applied to the planting groove. We can already check the differences in appearance in the two varieties, RB 86 1816 and RB 96 6928.In the areas with H2COPLA we have more complete and closed streets, with better health and vigor plants, unlike what we see in the witness areas (Producer Standard).With Anderson Rovari and Dennys Micky Martins Lima, CTV of @coplacana - Pride of Agro, branch of Jataí, Goiás.H2COPLA can be applied to the seedling nursery, in the planting groove, in the cutting of the base, in the initial foliar or in pre-harvest. Always bringing excellent return on investment!@plant_phcbrasil FOLLOWS #BREAKINGTHEPRODUCTIVITY BARRIERS WITH H2COPLA, THE GREATEST ALLY OF THOSE WHO PRODUCES!#agro #agronegócio #harpin #H2COPLA #sustentabilidade #bioinsumos

[oapknob1] 07/7/2022 22:15

Brasil.First sales of H2COPLA at Citrus Culture in São Paulo!It is with great satisfaction that we announce the first sales of H2COPLA for the culture of Citrus, under the guidance of our DM Jhonatan Henrique and his colleague Alex Bazzo, CTV of @ Coplacana - Pride of Agro, Iracemápolis branch.Harpin Protein (H2COPLA) brings various benefits to Citrus culture: improves root and vegetative development of the plant, homogeneity of flowering, and adhesion of flowers and fruits. Thus, it enables the plant to produce larger fruits, with higher concentration of sugars, as well as increasing fruit retention in the tree in pre-harvest and the durability of the fruits in post-harvest, representing increased productivity.A great challenge! These early customers have a very high expectation with respect to the product's benefits over Greening, or Huanglongbing (HLB), which is known, one of the most feared illnesses among citrus growers worldwide. Caused by the bacteria Candidatus liberibacter spp, it causes branch feces, dryness and death. The fruits show irregular ripening, reduction in size, deformation and intense fall.We all want to see the benefits that the application will bring by reducing the impact that Greening has brought on Paulist citrus farming. Let's keep it up!If you're also a citrus producer, try H2COPLA and feel the increased productivity in your orchard. The first application of the cycle occurs after harvest, in pre-blooming.Contact the @coplacana branch - Agro Pride closest to you for more information.H2COPLA, the ultimate ally of the producer!It's @Plant Health Care Brazil #breakingproductivitybarriers in Citrus culture#agro #agronegócio #phc #harpin #h2copla #citrus #greening #bioinsumos #sustentabilidade

[oapknob1] 28/6/2022 09:08

You believe it ?

[pretax2] 22/6/2022 21:16

There a write up on LSE from a poster called BOTs.

[cerrito] 22/6/2022 14:19

Anyone make the AGM??
I did not what with the tube strikes and I had a couple of webinars.
I see about 60pc voter turnout which is high for an AIM company but what I would expect given their shareholder base.
Heaven knows why 23pc voted against the AR and accounts

[pretax2] 16/6/2022 22:36

Just love those largeish trades being reported well after the close.
Why not report them on time?

[oapknob1] 10/6/2022 07:18

Half year trading update last year was 26th July.